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Abstract
Zygomycosis of the central nervous system (CNS) can manifest in three distinct clinical forms, as rhinocerebral zygomycosis, as disse-
minated zygomycosis with CNS involvement, and as isolated cerebral zygomycosis. We present a case of a 2-year-old boy with leu-
kaemia and disseminated zygomycosis, caused by Absidia corymbifera, involving the brain, spinal cord, lung and liver. The child received
treatment with liposomal amphotericin B and posaconazole for 6 months. Although the lesions of the lungs and liver resolved, those
of the CNS persisted and the child is in a vegetative state. A review of the literature after 2004 identiﬁed ten additional cases of dis-
seminated zygomycosis with cerebral involvement, all but one of which had concurrent lung infection. The most common underlying
disease in these cases was haematological malignancy and the mortality rate was 70%. Disseminated zygomycosis with cerebral invol-
vement is a fatal disease. Early recognition and prompt intervention with combined medical and surgical treatment may improve the
outcome.
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Introduction
Zygomycosis is an invasive, life-threatening fungal infection
that mainly affects immunocompromised hosts. Zygomycetes
can invade virtually any tissue or organ, resulting in a variety
of clinical presentations. The central nervous system (CNS)
can be invaded by Zygomycetes either contiguously from
adjacent paranasal sinuses, or haematogenously from a
remote site of infection. Zygomycosis of the CNS can pre-
sent in three distinct clinical forms, as rhinocerebral zygomy-
cosis, as disseminated zygomycosis with CNS involvement,
and as isolated cerebral zygomycosis. Rhinocerebral zygomy-
cosis is the most frequent form of CNS zygomycosis and has
been well described in the literature [1], whereas dissemi-
nated zygomycosis with brain involvement and isolated cere-
bral zygomycosis are rarer forms of the disease. In this
report, we present a boy with acute myeloid leukaemia and
disseminated zygomycosis with involvement of the CNS and
we review the relevant literature.
Illustrative Case Report
A 2-year-old boy was admitted to hospital because of acute
myeloid leukaemia. Two days after admission, he received
induction chemotherapy with cytosine-arabinoside, thiogua-
nine and idarubicin. Two weeks later, while on antimicrobial
treatment for a febrile episode, his fever recurred and his
leukocyte count was 310 cells/lL. The antimicrobial regimen
was changed to meropenem and teicoplanin, and liposomal
amphotericin B (L-AmB) (5 mg/kg) was added. Over the next
3 days the patient developed multiple focal seizures. Com-
puted tomography (CT) of the brain revealed a ring-
enhanced lesion extending into both parietal lobes and the
patient was started on corticosteroids and phenyntoin
(Fig. 1a). Chest CT showed extensive inﬁltrates in both lungs
with bilateral pleural effusion. A CT scan of the abdomen
revealed two low density areas in the liver (Fig. 1b). Subse-
quently, the patient developed status epilepticus and quadri-
paresis, was intubated and was transferred to the intensive
care unit. Direct microscopy of the pleural ﬂuid revealed
fungal hyphae. All cultures from blood, pleural ﬂuid, bronch-
oalveolar lavage and cerebrospinal ﬂuid were negative for
bacteria and fungi. Serum galactomannan and polymerase
chain reaction (PCR) for Aspergillus were negative. A brain
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biopsy revealed fungal hyphae consistent with Aspergillus. The
child was treated with voriconazole and caspofungin along
with intraventricular AmB for 1 month. He remained febrile
and his clinical condition was unchanged. Magnetic resonance
imaging (MRI) of the brain revealed new lesions and MRI of
the spine showed hypodense lesions extending from the cer-
vical to the lumbar spinal cord area (Fig. 1c). In light of these
ﬁndings, parafﬁn-embedded brain tissue was re-examined
using a semi-nested PCR speciﬁc for Zygomycetes and
sequencing of the amplicon identiﬁed the fungus to be Absidia
corymbifera [2]. The patient was then treated with posacona-
zole (25 mg/kg) and L-AmB (7 mg/kg) for 6 months. He
defervesced, the lung and liver lesions disappeared, but the
brain and spinal cord lesions remained unchanged. Six
months after discontinuation of antifungal therapy, the
patient is alive but in a vegetative state and his leukaemia is
in remission.
Discussion
The case presented here underlines the diagnostic and thera-
peutic difﬁculties involved in the management of cerebral
fungal infections. The diagnosis of CNS zygomycosis is often
difﬁcult because the clinical and radiological ﬁndings are non-
speciﬁc. For a deﬁnitive diagnosis, histology and culture are
needed. Histological identiﬁcation of fungus, however, may
be incorrect and cultures are positive in <70% of cases [3].
In our patient, the fungus had been misidentiﬁed as Aspergillus
based on hyphal morphology, which resulted in the adminis-
tration of inappropriate treatment for a month. The correct
identiﬁcation of fungus as Absidia corymbifera was made by
PCR in parafﬁn-embedded tissue after conventional means
had failed to allow the diagnosis. In addition to the diagnostic
difﬁculties, the management of fungal infections with CNS
involvement is problematic as a result of the poor response
of the CNS to standard antifungal therapy. With the adminis-
tration of L-AmB and posaconazole, the lung and liver lesions




FIG. 1. (a) Computed tomography (CT) scan showing a large, hypo-
dense, interhemispheric mass lesion with ring contrast enhancement
compressing both lateral ventricles with extensive surrounding
oedema. (b) Abdominal CT scan showing two low density areas, one
in the right liver lobe and the other in the border between the right
and left lobes. (c) Spine magnetic resonance imaging T2-weighted
image showing extensive intramedullary oedema of the thoracic
spinal cord (white arrows) and epidural ﬂuid entrapment at the thor-
acolumbar junction (black arrows).
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The CNS can be invaded by Zygomycetes either contigu-
ously from adjacent structures (i.e. the sinuses) or haemato-
genously from a remote site of infection in the lungs,
gastrointestinal tract, skin or other organ. In a recent study
analysing all cases of zygomycosis published up to 2004,
among 283 patients with CNS involvement, 196 (69%) had
rhinocerebral infection, 42 (15%) had disseminated disease
with involvement of the brain, and 45 (16%) had isolated cer-
ebral zygomycosis without any other foci of infection [3]. In
the same study, patients who had received deferroxamine
therapy presented more frequently with generalized dissemi-
nated zygomycosis, compared with other host categories.
There were no patients with diabetes who had haematogen-
ous dissemination to the brain. Instead, all CNS infections in
patients with diabetes occurred in those with rhinocerebral
infection. By contrast with rhinocerebral and disseminated
zygomycosis, isolated cerebral zygomycosis was found mainly
in immunocompetent patients who were abusing drugs intra-
venously [3].
In a review of the English literature since 2004, we identi-
ﬁed ten additional cases of disseminated zygomycosis with
cerebral involvement (Table 1). Of these ten patients and
the case presented here, ten had concurrent lung infection
(90%). The most common underlying disease was haematolo-
gical malignancy (64%). A total of 63% of the patients had
positive cultures: ﬁve yielded Rhizopus spp., one Rhizomucor
spp., one Cunninghamella bertholletiae, and in the patient
presented here the fungus species was identiﬁed as Absidia
corymbifera by a Zygomycetes-speciﬁc PCR [2].
Zygomycetes rapidly invade the walls of blood vessels,
resulting in infarction, haemorrhage or abscess formation.
When cerebral zygomycosis occurs in the context of disse-
minated infection, mainly in immunocompromised patients,
the involved areas may be the eye, the optic nerve or the
brain parenchyma (including the frontal and temporal lobes).
Alternatively, zygomycosis may present as cavernous sinus
thrombosis. In addition, zygomycotic lesions may be found in
the spinal cord as a result of acute or subacute infarction.
Various patterns are seen on MRI, but the central grey mat-
ter is usually the most severely affected [4]. The infarction is
more common in the thoracolumbar junction, especially in
the conus medullaris, because the collateral supply to the
anterior spinal artery is relatively sparse in this region. Infarc-
tion of the cervical segment is rare because of the abundant
blood supply by radicular arterioles of this area [4]. By con-
trast, most cases of isolated cerebral zygomycosis are loca-
lized at the basal ganglia or the thalamus and the lesions are
usually unilateral [5,6].
Treatment of CNS zygomycosis is most successful when a
multi-modal approach, using surgery and antifungal medica-
tion, is used. The prognosis, however, remains dismal, espe-
cially in disseminated infections. In the past, high doses of
AmB deoxycholate were the only available option. Lipid for-
mulations of AmB provide a useful alternative in that they
allow the administration of higher doses for longer periods
of time. The most commonly used antifungal therapy in CNS
zygomycosis is L-AmB. Its use is also supported by studies in
animals. In a murine model of disseminated zygomycosis,
Ibrahim et al. [7] showed that high-dose L-AmB (7.5 mg/kg)
treatment was more effective than standard AmB or a lower
dose of L-AmB (2.5 mg/kg). In a maximum-tolerated dose
study of L-AmB, dosages as high as 10 mg/kg per day were
TABLE 1. Case reports of disseminated zygomycosis with central nervous system involvement published after 2004
References
Age,
years Sex Underlying disease Organs involved Fungal species Treatment Outcome
Almyroudis et al. [11] 45 M Lung transplantation Brain, lung, myocardium, kidney,
small and large intestine and
thyroid gland
Culture negative Amphotericin B Death
Horger et al. [4] 62 F Multiple myeloma Brain, spinal cord, heart, lung Rhizopus sp. None Death
43 M AML Lung, ethmoid, sphenoid and
maxillary sinus, orbit, brain
Rhizopus sp. AmBisome Death
Hampson et al. [12] 68 M Diabetes,
desferroxamine therapy





Kannan et al. [13] 18 M Allogeneic BMT, GVHD Brain, lung Rhizopus sp. Systemic antifungal Survival
Revankar et al. [14] 46 M Diabetes mellitus Rhinocerebral, lung Rhizopus sp. Abelcet, AmBisome Cure
Vahid et al. [15] 32 M AML Lung, liver, brain Unspeciﬁed NA NA
Singh et al. [16] 65 M Rheumatoid arthritis,
anti-TNF (adalimumab)
Lung, brain NA Amphotericin B Death
Uckay et al. [17] 40 F BMT, GVHD, deferroxamine,
hyperglycaemia
Lung, heart, brain Rhizomucor sp. None Death
35 M BMT, GVHD Rhinocerebral, stomach,
intestines, lung
Rhizopus sp. Amphotericin B
deoxycholate
Death
Current case 2 M AML Lung, liver, brain, spinal cord Absidia corymbifera AmBisome, posaconazole Survival, with
neurological sequelae
M, male; F, female; AML, acute myelogenous leukaemia; BMT, bone marrow transplantation; GVHD, graft-versus-host disease; NA, not available; TNF, tumour necrosis
factor.
48 Clinical Microbiology and Infection, Volume 15, Supplement 5, October 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 5), 46–49
suggested as beneﬁcial in CNS fungal infections that do not
respond to standard doses [8]. In isolated cerebral zygomy-
cosis there have been reports of treatment with endoscopic
debridement and intralesional administration of AmB in con-
junction with systemic L-AmB [9]. In recent years, posacona-
zole has been added to the antifungal armamentarium against
zygomycosis, with promising results [10]. The mortality rates
of disseminated zygomycosis with cerebral involvement in
cases reported before and after 2004 were 98% [2] and 70%
[4,11–17], respectively (Table 1).
Conclusions
In conclusion, disseminated zygomycosis with cerebral invol-
vement is a fatal disease. Early recognition and prompt inter-
vention with combined medical and surgical treatment may
improve the outcome.
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